Tech Company Financing Transactions
Eikonoklastes Therapeutics Funding Round
Eikonoklastes Therapeutics closed a Seed financing round on 7/23/2020. Backers included CincyTech and private investors.
Transaction Overview
Company Name
Announced On
7/23/2020
Transaction Type
Venture Equity
Amount
Unknown
Round
Seed
Investors
CincyTech (Lead Investor) (John Rice)
Proceeds Purpose
The seed round will enable the company to complete a confirmatory in vivo I.V. efficacy study, to study I.V. pharmacokinetics, and to initiate manufacturing scaleup.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
981 Hill St.
Cincinnati, OH 45202
USA
Cincinnati, OH 45202
USA
Phone
Website
Email Address
Overview
Eikonoklastes Therapeutics is advancing a new generation of tissue factor (TF) immunotherapies for the treatment of triple-negative breast cancer and other cancers and diseases with high morbidity and unmet clinical needs. Eikonoklastes' proprietary molecules are engineered for maximum efficacy and a superior safety profile.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Bruce Halpryn
Chief Medical Officer
Mark Dato
Co-Founder
Zhiwei Hu
VP - Bus. Development
Sam Lee
Browse more venture capital transactions:
Prev: 7/22/2020: FLX Distribution venture capital transaction
Next: 7/23/2020: Episode Six venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs